AroCell is, as a first step, developing an ELISA assay for easy and reproducible determination of TK in blood cancers, TK 210/hem ELISA. The ELISA method is a general method that can be used in all laboratories. It is, therefore, useful for clinical documentation and will provide AroCell with early revenues. As a second step AroCell will enter the routine diagnostic area through licensing of the new marker to the various market-leading platform companies within the routine diagnostic market segment. This will allow a quick penetration of the market since these companies have their own established sales organizations and are present worldwide with a large installed base of instruments.
AroCell will work through strategic partners for development, production and sales. Through Arocell´s industry expertise and experience, the company already has important, international contacts and currently holds partnership agreements with raw material producing companies and partners for test development and production. Development of the ELISA test is carried out in collaboration with an experienced external partner. Production partner has been selected. AroCell will remain directly responsible for the sales of the ELISA product, which will take place in selected countries through local distributors.
Adaptation to the automated systems will be carried out by the licensing companies themselves. The final product will be sold through their established sales organizations.
The same business model will be used for AroCell´s future products.
Most importantly, AroCell has to be responsible for clinical documentation and product development. Therefore, clinical and marketing competence will remain within AroCell, as well as the scientific knowledge about TK. In order to achieve market success with a new and unique product, genuine clinical documentation is essential.
For further information, please contact us at: